ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 298

In CCP Positive “At Risk of Rheumatoid Arthritis” Individuals, the Presence of Sub-clinical Synovitis in 4-10joints Universally Results in Clinical Synovitis

Laurence Duquenne1, Kulveer Mankia 2, Jacqueline Nam 2, Andrea Di Matteo 2, Leticia Garcia-Montoya 2 and Paul Emery 2, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, England, United Kingdom, 2Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: At-Risk of Inflammatory Arthritis, Doppler ultrasound and Risk Prediction

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: Imaging Of Rheumatic Diseases Poster I

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: In a cohort of Anti-Cyclic Citrullinated Peptide Positive (Anti-CCP+) At-Risk of developing inflammatory arthritis (IA) individuals without clinical synovitis, previous univariable analysis showed that the presence of a Power Doppler signal (PD) in at least one joint was predictive of progression (Nam, 2016).

Further analysis is required to examine the influence of the number of joints PD positive on the progression rates and incorporate this data in the already established 2010 ACR/EULAR criteria for Rheumatoid Arthritis (RA), replacing the swollen joint count by the PD positive joint count.
Objectives:

  1. To investigate the association between the number of joints with a Power Doppler signal and progression to IA.
  2. To include the PD positive joint count in the 2010 ACR/EULAR criteria for RA to improve prediction in individuals without synovitis.

Methods: Participants were selected by an anti-CCP positive test and a new musculo-skeletal symptom. Individuals with intermittent symptoms or clinical synovitis were excluded.

Using univariable cox regression, we described for the first time the predictive value of the number of joints with a Power Doppler signal.

By replacing the number of swollen joints, with the number of joints PD positive in the 2010 ACR/EULAR criteria for RA, we then analysed IA-free survival curves for participants without clinically swollen joints.

Results: 361 patients were followed for a mean of 24 months (Table 1). Of the 28% of participants who developed IA, 81% met the ACR/EULAR criteria for RA at progression. There were significantly more participants with high anti-CCP titres in the progressor group.
Using Cox univariable analysis, the results show that the probability of developing IA is significantly increased by a Hazard ratio of 1.89 if 1 to 3 small joints present a PD signal (p=0.012), and of 3.81 if 4 to 10 joints are PD positive (p< 0.001) (Figure 1). Furthermore, all participants presenting with 4 to 10 joints progressed, 60% of them in the first 2 years (Figure 1).
Using multivariable analysis and adding CCP titre and inflammatory markers to the PD positive joint count, Hazard Ratio for the probability of progression shows a risk 2.97 times higher (p >0.001, CI 1.96-4.49) for the participants who met the 2010 ACR/EULAR criteria for RA replacing the swollen joint score with the PD positive joint count (Figure 2).

Conclusion:

  1. All of the participants with 4 to 10 joints with a Power Doppler Signal progressed to IA (mainly RA), 60% of them in the first 2 years.
  2. The predictive value for progression to IA of ultrasound scans is not improved by the addition of CCP titres and inflammatory markers (when included in the 2010 ACR/EULAR criteria for RA using Power Doppler positive joint count in patient without clinical synovitis).


Disclosure: L. Duquenne, None; K. Mankia, None; J. Nam, None; A. Di Matteo, None; L. Garcia-Montoya, None; P. Emery, AbbVie, 2, 5, 9, BMS, 2, 5, Bristol-Myers Squibb, 2, 5, 9, Gilead, 5, Lilly, 2, 5, 9, MSD, 2, 5, 9, Novartis, 2, 5, 9, Pfizer, 2, 5, 9, Roche, 2, 5, 9, Samsung, 2, 5, 9, Samsung Bioepis Co., Ltd., 2, Sandoz, 2, 5, 9, UCB, 2, 5, 9.

To cite this abstract in AMA style:

Duquenne L, Mankia K, Nam J, Di Matteo A, Garcia-Montoya L, Emery P. In CCP Positive “At Risk of Rheumatoid Arthritis” Individuals, the Presence of Sub-clinical Synovitis in 4-10joints Universally Results in Clinical Synovitis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/in-ccp-positive-at-risk-of-rheumatoid-arthritis-individuals-the-presence-of-sub-clinical-synovitis-in-4-10joints-universally-results-in-clinical-synovitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/in-ccp-positive-at-risk-of-rheumatoid-arthritis-individuals-the-presence-of-sub-clinical-synovitis-in-4-10joints-universally-results-in-clinical-synovitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology